Aurobindo Pharma Limited Incorporates Wholly-Owned Subsidiary to Bolster Global and Domestic Operations
Aurobindo Pharma Limited has announced the incorporation of a new wholly owned subsidiary, 'Auropharm Overseas Limited,' signaling a strategic move to expand its manufacturing and marketing capabilities across both Indian and international markets. The company incorporated the subsidiary on August 13, 2026.The newly formed entity is dedicated to undertaking comprehensive manufacturing and marketing operations in India and foreign countries. This incorporation positions Aurobindo Pharma to strengthen its market presence through this specialized overseas arm while maintaining full ownership control.
Auropharm Overseas Limited falls under the pharmaceuticals industry. The subsidiary was incorporated as a wholly owned subsidiary, making it a related party to the parent company. Promoters of Aurobindo Pharma have no interest in the newly formed entity.
The initial capital structure and operational details of Auropharm Overseas Limited are summarized below:
| Detail | Specification |
|---|---|
| Subsidiary Name | Auropharm Overseas Limited |
| Industry | Pharmaceuticals |
| Incorporation Date | August 13, 2026 |
| Ownership Acquired | 100% |
| Nature of Consideration | Cash subscription to share capital |
| Share Capital Cost | Rs. 10,00,000 |
| Shares Issued | 1,00,000 equity shares at Rs. 10 each |
The incorporation of Auropharm Overseas Limited enables the company to conduct business operations specifically related to manufacturing and marketing in both domestic and international settings. No governmental or regulatory approvals were required for this incorporation.
AUROPHARMA Stock Price Movement
Aurobindo Pharma Limited shares slipped today in post-market trading, settling at ₹1663.4 after shedding 0.22% of its value. Despite the slight decline, the stock previously traded near its 52-week high of ₹1682.4, showcasing strong market interest in the pharmaceutical giant.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.